Brenton K. Ahrens - Sep 8, 2022 Form 4 Insider Report for Iterum Therapeutics plc (ITRM)

Role
Director
Signature
By: /s/ Nancy Levenson, as Attorney-in-Fact for Brenton Karl Ahrens
Stock symbol
ITRM
Transactions as of
Sep 8, 2022
Transactions value $
-$76,803
Form type
4
Date filed
9/12/2022, 09:01 PM
Previous filing
Jun 28, 2022
Next filing
Sep 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITRM Ordinary Shares Sale -$7.47K -3.3K -2.85% $2.26 112K Sep 8, 2022 See Footnote F1, F2, F3
transaction ITRM Ordinary Shares Sale -$34.7K -15K -13.36% $2.32 97.2K Sep 9, 2022 See Footnote F1, F3, F4
transaction ITRM Ordinary Shares Sale -$34.6K -15K -15.42% $2.31 82.2K Sep 12, 2022 See Footnote F1, F3, F5
holding ITRM Ordinary Shares 410 Sep 8, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of Ordinary Shares described herein reflect a 15:1 reverse stock split by the Issuer which became effective August 17, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 - $2.28, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"). Investment and voting decisions with respect to the securities held by the Canaan Fund are made by the managers of Canaan X, collectively. The Reporting Person, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. The Reporting Person disclaims Section 16 beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest therein, if any, in such securities by virtue of the limited liability company interests he owns in Canaan X.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.27 - $2.37, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 - $2.36, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.